RACY,Relativity Acquisition Corp. | Financials

Financials

RACY

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Relativity Acquisition Corp.RACY

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Relativity Acquisition Corp. does not have significant operations.

It focuses on effecting a capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the cannabis industry.

Relativity Acquisition Corp. was incorporated in 2021 and is based in Las Vegas, Nevada. Relativity Acquisition Corp. operates as a subsidiary of Relativity Acquisition Sponsor LLC.

Latest News >

Arch Capital Renews $1 Billion Share Repurchase Program

Dec 20, 2024

04:40 PM EST, 12/20/2024 (MT Newswires) -- Arch Capital Group ( ACGL ) said Friday it has renewed its share repurchase authorization of $1.0 billion, which may be effected from time to time in open market or privately negotiated transactions. The company said the new program replaces its existing buyback authorization. ...

US FDA declines to approve Lexicon Pharma's add-on diabetes drug

Dec 20, 2024

Dec 20 (Reuters) - The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals' ( LXRX ) add-on drug for type 1 diabetes and chronic kidney disease, the company said on Friday. ...

Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku

Dec 20, 2024

Dec 20 - Japanese drugmaker Nippon Shinyaku ( NPNKF ) infringed a Sarepta patent related to its Duchenne muscular dystrophy (DMD) drug Vyondys 53 and must pay $115.2 million in damages, a Delaware jury said on Friday. The jury also rejected competing patent claims by Shinyaku, which had accused Sarepta of violating its patent rights in its DMD drug Viltepso....

Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea

Dec 20, 2024

Dec 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Eli Lilly's ( LLY ) weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with the common sleeping disorder. The regulator approved the drug for moderate to severe obstructive sleep apnea in adults with obesity, the company said. Sleep...